Split History
8% "No Withdrawal" Portfolio »    DMPI Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. According to our DMPI split history records, DelMar Pharmaceuticals has had 1 split.
DMPI split history picture
DelMar Pharmaceuticals (DMPI) has 1 split in our DMPI split history database. The split for DMPI took place on May 08, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of DMPI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as DelMar Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the DMPI split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into DelMar Pharmaceuticals shares, starting with a $10,000 purchase of DMPI, presented on a split-history-adjusted basis factoring in the complete DMPI split history. DMPI split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/07/2013
End date: 11/12/2019
Start price/share: $24.50
End price/share: $0.73
Dividends collected/share: $0.00
Total return: -97.00%
Average Annual Total Return: -40.80%
Starting investment: $10,000.00
Ending investment: $300.17
Years: 6.69
Date Ratio
05/08/20191 for 10
DMPI is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

DRAD Split History
DSCI Split History
DSCO Split History
DVA Split History
DVAX Split History
DYNT Split History
ECTE Split History
EIGR Split History
ELGX Split History
ENSG Split History

Also explore: DMPI shares outstanding history

TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
Cancer Genetics, Inc. (CGIX)
Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3X Shares (GUSH)
Kingold Jewelry, Inc. (KGJI)
Aethlon Medical, Inc. (AEMD)
Aberdeen Standard Physical Gold Shares ETF (SGOL)
Safe-T Group Ltd. (SFET)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

DMPI Insider Buying

DMPI Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.